5 Stocks Delivering Eye-Popping Gains

4. Erasca Inc. (NASDAQ:ERAS)

Erasca snapped a four-day losing streak on Thursday, soaring 16.90 percent to close at $10.65 apiece, as investors resorted to bargain-hunting following a steep plunge in the previous trading days, with sentiment fueled by renewed optimism for its cancer treatment candidate.

It can be recalled that shares of Erasca Inc. (NASDAQ:ERAS) fell sharply in the past few days following the confirmation of the death of a patient previously enrolled in the first phase of clinical study for its treatment candidate, ERAS-0015.

In a call with analysts, the company said that a 66-year-old man succumbed after electing to withdraw supportive care during the trial after developing Grade 3 pneumonitis on 24 mg.

Erasca Inc. (NASDAQ:ERAS), however, deemed the case a “rare event.”

Despite the incident, Erasca Inc. (NASDAQ:ERAS) maintained ERAS-0015 as potentially the best-in-class amid positive preliminary data from the first phase across all other enrolled patients.

According to the company, ERAS-0015 demonstrated favorable response rates, with more than half of enrolled lung cancer patients seeing their tumors shrink, and around 50 percent of pancreatic cancer patients saw shrinkage.

ERAS-0015 also demonstrated a favorable safety profile and recorded only low-grade adverse events.

“We are thrilled with the robust efficacy results demonstrated so far by our pan-RAS inhibitor ERAS-0015 in patients with lung and pancreatic cancer. The magnitude of clinical benefit seen during dose escalation is particularly striking and compares favorably with other pan-RAS, pan-KRAS, or KRAS-mutant selective inhibitors,” said Erasca Inc. (NASDAQ:ERAS) Chairman and CEO Jonathan Lim.

“Notably, preliminary data support ERAS-0015 may be combined with standard-of-care doses of panitumumab, positioning it as a potential backbone therapy for future combination regimens. Together, we believe these findings support the best-in-class potential of ERAS-0015, and we look forward to continued progress in our Phase 1 monotherapy dose expansion cohorts and combination dose escalation cohorts,” he noted.